%PDF-1.3
%
2 0 obj
<>
endobj
5 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
19 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
16 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
10 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
11 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
9 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
15 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
4 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
8 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
3 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
1 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
6 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
14 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
18 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
7 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
17 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 53/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
12 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 54/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T R
Ɩf
!\!Y\ !p )P
endstream
endobj
13 0 obj
<>>>/Subtype/Form/BBox[0 0 612 792]/Matrix [1 0 0 1 0 0]/Length 55/FormType 1/Filter/FlateDecode>>stream
xs
w3T04PI2P0T5T0P02S04S @$P5 )1
endstream
endobj
20 0 obj
<>stream
3B2 Total Publishing System 7.51o/W
2011-01-11T05:29:17-08:00
2010-12-28T10:20:36+05:30
application/pdf
untitled
Acrobat Distiller 8.1.0 (Windows)
uuid:9b064784-655a-4d28-b32c-acf3ad805c33
uuid:e5cbbe59-0697-41f7-87d2-47c64c6de8c1
endstream
endobj
21 0 obj
<>stream
x+ |
endstream
endobj
22 0 obj
<>stream
xS**T0T0 BiU)D* 9V
endstream
endobj
23 0 obj
<>stream
x+ |
endstream
endobj
24 0 obj
<>stream
xS**T0T0 BiU !D. _e1
endstream
endobj
25 0 obj
<>stream
x+ |
endstream
endobj
26 0 obj
<>stream
xS**T0T0 BiUD* :
endstream
endobj
27 0 obj
<>stream
x+ |
endstream
endobj
28 0 obj
<>stream
xS**T0T0 BiUD* 8
endstream
endobj
29 0 obj
<>stream
x+ |
endstream
endobj
30 0 obj
<>stream
xS**T0T0 Bih]9D. qaj
endstream
endobj
31 0 obj
<>stream
x+ |
endstream
endobj
32 0 obj
<>stream
xS**T0T0 Bih] D. pa
endstream
endobj
33 0 obj
<>/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]/XObject<>/Font<>>>/Thumb 42 0 R/MediaBox[0 0 612 792]/Rotate 0>>
endobj
43 0 obj
<>/ProcSet[/PDF/Text/ImageB]/XObject<>/Font<>>>
endobj
35 0 obj
<>stream
/GS1 gs
BT
/F4 1 Tf
8.9663 0 0 8.9663 62.022 725.7825 Tm
0 0 0 rg
0 Tc
0 Tw
[(radiosensitizing)-191.9(chemotherapy)-183.4(\(2\).)-186.7(Although)-185.1(median)-183.9(survival)]TJ
0 -1.2203 TD
[(among)-469.2(these)-466.5(patients)-471.5(did)-464.8(not)-468.2(differ)-469.6(signicantly)-466.1(from)-469.4(the)]TJ
0 -1.2266 TD
[(group)-295.1(as)-298(a)-296.7(whole)-295.7(or)-294.3(from)-292.4(those)-298.7(receiving)-299.9(conventional)-300.9(post-)]TJ
0 -1.2203 TD
[(op)21.2(er)18.4(at)19(iv)14.7(e)-297.1(r)0(a)25.1(d)0(i)18.8(a)0(t)19(i)0(o)19(n)-300.6(t)12.2(h)0(e)15.7(r)0(a)18.8(p)0(y)-284(a)0(l)22.2(o)0(n)12.8(e)12.8(,)-293.8(a)-296.7(g)0(r)20.2(e)0(a)13.2(t)12.2(er)-285.1(pr)16.9(op)21.2(or)15.5(t)12.2(i)0(o)19(n)-300.6(of)-287.8(pa)18.1(-)]TJ
T*
[(ti)21.3(en)15.7(t)12.2(s)-203.6(su)16.3(rv)17.5(i)15.4(v)0(e)18.3(d)-205.3(lo)19(ng)17.5(e)12.8(r)-203(t)12.2(h)0(a)16.1(n)-199.4(1)-201.8(y)0(e)14.7(a)13.1(r)-203(\()12.2(23)19.9(%)-204(v)0(s)16.9(.)]TJ
/F5 1 Tf
18.1531 0 TD
(<)Tj
/F4 1 Tf
.7714 0 TD
[(1)13.1(0)0(%)17.8(\))0()19.5(s)0(u)16.3(g)14.6(ge)14.7(st)23.5(in)18.4(g)]TJ
-18.9245 -1.2266 TD
[(pe)17.7(rh)21.2(ap)18.1(s)-336.4(t)12.2(ha)16.1(t)-329.3(s)0(y)19.6(s)0(t)17.2(e)0(m)21.5(i)0(c)-325.3(c)0(h)16.3(e)12.8(mo)18.6(th)15.1(e)12.8(r)0(a)18.8(p)0(y)-321.9(m)0(i)17.9(g)0(h)17.5(t)-329.3(ha)16.1(ve)-323.1(po)21.2(te)18.6(nt)15.1(ia)22.2(l)-332.3(t)0(o)]TJ
0 -1.2203 TD
[(tr)17.8(e)12.8(a)0(t)-379.4(m)0(i)17.9(c)13.4(ro)15.5(me)21.5(ta)19(st)17.2(a)13.1(t)0(i)15(c)-385(di)18.8(se)17.8(a)13.1(s)0(e)-380.6(a)13.1(nd)-379.4(a)13.1(f)0(f)18(e)0(c)13.5(t)-386.2(im)24.2(pr)16.9(ov)21.8(ed)-382.3(lo)19(ng)23.8(-t)18(er)18.4(m)]TJ
T*
[(su)16.3(rv)23.9(iv)14.7(a)13.1(l)0(.)-234.1(O)0(u)20.9(r)-247.3(e)12.8(x)0(p)15.5(e)12.8(ri)21.1(en)15.7(ce)-233.1(ha)16.1(d)-236.9(a)0(l)15.9(s)0(o)-231.7(b)0(e)21(e)0(n)-237.2(t)12.2(ha)16.1(t)-240.7(a)0(l)15.9(m)15.1(os)14.9(t)-240.7(a)0(l)15.9(l)-243.8(pa)24.4(ti)15(e)12.8(n)0(t)15.1(s)]TJ
0 -1.2266 TD
[(su)16.3(c)13.4(c)0(u)18.3(m)0(b)-381.4(t)12.2(o)-394.8(m)0(e)21.5(t)0(a)19(s)0(t)17.2(a)13.1(ti)15(c)-385(d)0(i)18.8(s)0(e)17.8(a)0(s)18.1(e)-391.9(e)12.8(v)0(e)18.3(n)-389.1(if)-383.4(di)18.8(se)17.8(a)13.1(s)0(e)-380.6(c)0(o)16.9(u)0(l)20.4(d)-388.7(be)-383.7(c)13.4(o)0(n)12.8(-)]TJ
0 -1.2203 TD
[(tr)17.8(ol)19(le)21.9(d)-325.5(i)15.4(n)-325.9(t)12.2(he)-313.1(ne)15.7(c)13.4(k)0(,)-310.8(s)0(o)-313.9(i)0(t)-313.8(w)0(a)24.2(s)-323.8(c)13.4(l)0(e)15.5(a)13.1(r)-323.2(t)0(o)-313.1(u)0(s)-312.5(t)12.2(ha)16.1(t)-322.9(A)0(T)20.9(C)-322.6(i)15.4(n)-325.9(mo)18.6(st)-311.6(a)13.1(l)0(l)]TJ
T*
[(pa)18.1(t)12.2(i)0(e)15.5(n)0(t)21.4(s)-368(is)-358.9(a)-366.2(s)0(y)19.6(s)0(t)17.2(e)0(m)21.5(i)0(c)-363.2(d)0(i)18.8(s)0(e)24.1(a)0(s)18.1(e)0()20.1(e)0(v)18.3(e)0(n)-357.4(a)0(t)-360.4(t)0(h)15.1(e)-366.6(t)12.2(i)0(m)17.9(e)-366.6(of)-357.3(in)18.4(it)15(ia)22.3(l)-370.3(d)0(i)18.8(-)]TJ
T*
[(ag)21.4(no)19.1(si)14.1(s.)-238.2(Mo)17.4(re)18.4(ov)21.8(er)18.4(,)-249.5(i)0(t)-244.3(w)0(a)17.8(s)-247.9(di)18.8(sh)20.6(ea)19.6(rt)17.8(en)15.7(in)18.4(g)-251(t)12.2(o)-249.4()0(n)18.9(d)-255.9(i)15.4(n)-256.3(ou)21.2(r)-253.6(o)0(r)21.8(i)0(g)17.3(i)0(n)18.4(a)13.1(l)]TJ
0 -1.2266 TD
[(se)17.8(ri)21.1(es)-355.3(t)12.2(h)0(a)16.1(t)-360.9(c)13.4(o)0(n)12.8(v)0(e)24.7(n)0(t)15.1(i)0(o)19(n)0(a)22.4(l)-363.9(ex)16.9(t)12.2(e)0(r)18.4(n)0(a)16.1(l)-357.6(be)21(am)-351.2(ra)18.8(di)18.8(a)13.1(t)0(i)15(o)0(n)-353.9(t)12.2(he)15.7(ra)25.1(py)-353.5(di)18.8(d)]TJ
0 -1.2203 TD
[(no)19.1(t)-500(a)0(l)15.9(t)12.2(er)-493.8(t)12.2(h)0(e)-490.1(c)0(h)16.3(a)13.1(nc)16.3(e)12.8(s)-500.8(of)-496.4(l)15.4(o)0(c)16.9(o)0(r)15.5(e)12.8(gi)17.3(on)19.1(a)13.1(l)-503(t)12.2(u)0(m)20.1(o)0(r)-490.3(r)0(e)18.4(c)0(u)18.3(r)0(r)17.6(e)12.8(nc)16.3(e,)-489.7(al)15.9(-)]TJ
T*
[(th)15.1(ou)21.2(gh)-260.7(it)-263.2(di)25.1(d)-274.9(a)13.1(pp)16.3(e)12.8(a)0(r)-259.5(t)0(o)-262.5(s)0(o)14.9(m)15.1(ew)17.4(ha)16.1(t)-266(d)0(e)16.1(l)0(a)22.3(y)-270(it)15(s)-266.9(d)0(e)16.1(v)0(e)18.3(l)0(o)19(p)0(m)20.1(e)12.8(nt)-263.1(\(2)19(\))12.2(.)]TJ
1.1128 -1.2266 TD
[(We)-264.5(therefore)-273.8(postulated)-272.9(that)-275.7(to)-268.8(make)-267(progress)-271.7(and)-265.1(extend)]TJ
-1.1128 -1.2203 TD
[(survival)-245.4(in)-240.9(ATC,)-241.4(a)-239.8(two-pronged)-242.2(approach)-248.2(would)-239.9(be)-238.3(required)]TJ
T*
[(to)-407.9(both)-403.1(more)-405.6(effectively)-404.6(treat)-405.7(locoregional)-411.8(disease)-400.5(while)-410.3(in)]TJ
0 -1.2266 TD
[(parallel)-327.7(preemptively)-329.5(aggressively)-327.2(treating)-328.5(occult)-322.8(metastatic)]TJ
0 -1.2203 TD
[(disease.)-321.2(Hence,)-315.2(beginning)-321.2(in)-316.7(2003,)-317.1(patients)-319.8(with)-318.8(operable)-315.6(or)]TJ
T*
[(inoperable)-341.5(nonmetastatic)-346.7(ATC)-333.4(\(stages)-342.5(IV)-340(A)-336.5(and)-341(B\))-338.6(who)-336.6(de-)]TJ
T*
[(sired)-539.6(an)-540.3(aggressive)-540.5(approach)-539(were)-539.6(routinely)-544.9(offered)-538.3(and)]TJ
0 -1.2266 TD
[(treated)-522.4(with)-521.2(individualized)-524.3(intensity)-526.2(modulated)-523.3(radiation)]TJ
0 -1.2203 TD
[(therapy)-553.5(\(IMRT\))-552.9(and)-549.7(radiosensitizing)-558.6(as)-550.9(well)-546(as)-550.9(adjuvant)]TJ
T*
[(chemotherapy.)-287.5(IMRT)-286.4(was)-287(utilized)-286.7(because)-290.2(of)-281.4(its)-289.8(more)-285.5(favor-)]TJ
0 -1.2266 TD
[(able)-241.3(dose)-240.9(distributions,)-241.4(allowing)-243.6(optimal)-242.7(dose)-240.9(delivery)-237(to)-243.5(the)]TJ
0 -1.2203 TD
[(target)-340.6(volume)-347.3(while)-340.8(minimizing)-342.4(dose)-342.1(to)-338.4(uninvolved)-344.8(organs)]TJ
T*
[(including)-234.1(the)-237.7(larynx,)-231.6(esophagus,)-239.6(and)-233.5(lung)-234(\(36\).)-236.3(Doxorubicin)]TJ
0 -1.2266 TD
[(was)-312.3(chosen)-313.5(as)-310.6(one)-309.6(of)-313.1(the)-313.6(chemotherapeutic)-316.3(agents)-312.5(to)-313.1(be)-307.8(uti-)]TJ
0 -1.2203 TD
[(lized)-300.3(because)-302.9(of)-300.4(its)-302.5(known)-300.1(activity)-302.8(in)-297.8(advanced)-305.5(ATC)-301.7(and)-296.8(its)]TJ
T*
[(radiation)-338.9(sensitizing)-340.4(properties)-347.1(\(715\).)-337(A)-336.5(taxane,)-343(either)-336.7(doc-)]TJ
0 -1.2266 TD
[(etaxel)-542.9(or)-534.6(paclitaxel,)-540.5(was)-539.9(also)-538.3(chosen)-541.2(to)-534.4(be)-535.4(added)-539.5(to)-540.7(the)]TJ
0 -1.2203 TD
[(doxorubicin)-709.8(and)-707.7(radiation)-705.6(therapy)-711.6(because)-707.5(of)-705.1(reported)]TJ
T*
[(promising)-189.3(activity)-182.7(against)-189.2(advanced)-185.4(ATC)-181.6(\(16\),)-186.2(the)-187.1(established)]TJ
T*
[(synergy)-593.9(between)-597.6(taxanes)-594.3(and)-587.6(doxorubicin)-596(\(17,18\))-596.3(and)-593.9(a)]TJ
0 -1.2266 TD
[(known)-388.6(safety)-385.5(prole)-384.3(with)-388.4(the)-383.1(administration)-389.4(of)-382.6(the)-389.5(combi-)]TJ
0 -1.2203 TD
[(nation)-209.1(of)-205.6(doxorubicin,)-206.9(a)-201.8(taxane,)-203.9(and)-208.2(radiation)-206.1(therapy)-205.8(\(18,19\).)]TJ
T*
[(The)-221.3(present)-228.3(report)-227.2(details)-219.9(the)-225.1(long-term)-228.2(outcomes)-226.7(for)-218.9(the)-225.1(rst)]TJ
0 -1.2266 TD
[(10)-353.1(consecutive)-353.4(patients)-357.7(treated)-351.7(in)-354.7(accord)-352.3(with)-350.5(these)-359(revised)]TJ
0 -1.2203 TD
[(practice)-282.2(guidelines.)]TJ
/F6 1 Tf
0 -3.054 TD
(Methods)Tj
/F4 1 Tf
1.1128 -1.8336 TD
[(This)-390.6(retrospective)-403.1(analysis)-389.6(analyzing)-394.3(outcomes)-397.5(from)-393.5(our)]TJ
-1.1128 -1.2203 TD
[(practice)-427.7(change)-433.5(was)-426.1(approved)-426.7(by)-426.1(the)-433.7(Mayo)-422.8(Clinic)-430.8(Institu-)]TJ
27.9978 53.7764 TD
[(tional)-215.5(Review)-218.6(Board.)-207.9(In)-214.2(accordance)-215.3(with)-211.4(Minnesota)-221.7(state)-210.3(law,)]TJ
0 -1.2203 TD
[(only)-248.1(patients)-243.9(who)-248.1(authorized)-248.1(review)-240.3(of)-249.8(their)-241.9(medical)-246.6(records)]TJ
0 -1.2266 TD
[(for)-339.1(research)-346.1(were)-337.2(included)-339.5(in)-342(this)-337.5(report.)-337.6(The)-341.4(medical)-341.4(diag-)]TJ
0 -1.2203 TD
[(nostic)-579.8(index)-574.7(and)-575(Cancer)-578.3(Registry,)-578.3(institutional)-577.4(databases)]TJ
T*
[(listing)-367.9(all)-367(patient)-369(diagnoses,)-363.5(were)-368.9(searched)-367.4(electronically)-365.2(to)]TJ
0 -1.2266 TD
[(identify)-246.3(all)-246.8(newly)-240.5(diagnosed)-242.1(patients)-250.2(with)-243(and/or)-240(treated)-244.2(for)]TJ
0 -1.2203 TD
[(ATC)-390.3(between)-382.7(January)-388.7(1,)-381.8(2003,)-386.7(and)-379(December)-388.8(31,)-381.3(2007.)-386.7(Pa-)]TJ
T*
[(tients)-363.2(with)-363.1(undifferentiated)-364.4(thyroid)-359.7(cancers)-363.8(\(grade)-355.8(3/4\))-362.9(not)]TJ
0 -1.2266 TD
[(meeting)-249.4(review)-253(criteria)-247.9(for)-244.2(ATC)-244.8(\(grade)-248.3(4/4\))-249.1(were)-242.4(specically)]TJ
0 -1.2203 TD
[(excluded)-208.1(from)-197.5(this)-204.7(case)-202.3(series.)-205.6(January)-199(2003)-200.4(was)-204.8(chosen)-206.1(as)-196.8(the)]TJ
T*
[(beginning)-188.5(date)-186.2(for)-187.3(the)-180.8(study)-187.6(because)-189(this)-185.7(is)-181.9(the)-187.1(date)-179.9(that)-187.2(IMRT)]TJ
T*
[(for)-231.6(thyroid)-226.9(cancer)-229.7(was)-230.1(introduced)-226.1(into)-231.5(our)-226.1(clinical)-230.6(practice.)-228.3(A)]TJ
0 -1.2266 TD
[(total)-392.5(of)-388.9(25)-384.7(new)-384.3(ATC)-390.3(patients)-389.3(were)-387.8(identied)-386.5(in)-386.3(this)-388.1(5-year)]TJ
0 -1.2203 TD
[(interval:)-381.4(10)-378.4(\(40%\))-374.6(presented)-383(with)-375.7(distant)-378.4(metastatic)-381.4(disease)]TJ
T*
[(and)-461.2(underwent)-462.7(palliative)-464.5(treatment,)-466.9(whereas)-461.6(5)-454.8(\(20%\))-463.2(pre-)]TJ
0 -1.2266 TD
[(senting)-288.3(with)-287.2(regionally)-284.9(conned)-286.6(disease)-286.7(elected)-290.5(treatment)-286.9(at)]TJ
0 -1.2203 TD
[(their)-286.2(local)-280.5(institutions)-284.8(\(Scheme)-289.8(1\).)]TJ
1.1128 -1.2203 TD
[(Of)-345(the)-338.9(remaining)-344.7(10)-340.5(consecutive)-347(patients)-345.1(\(40%)-336.2(of)-344.7(all)-341.7(new)]TJ
-1.1128 -1.2266 TD
[(ATC)-333.4(patients)-338.7(seen)-333.3(at)-328.8(our)-333.6(institution\))-334.5(all)-329.1(had)-334.7(regionally)-329.2(con-)]TJ
0 -1.2203 TD
[(ned)-255.9(ATC,)-247.8(all)-253.2(were)-248.7(of)-249.8(good)-253.2(performance)-252.1(status,)-253.9(and)-252.5(all)-246.9(were)]TJ
T*
[(offered)-437.2(an)-426.5(aggressive)-433.1(approach)-431.5(in)-430.6(accord)-434.5(with)-426.3(our)-434.8(altered)]TJ
T*
[(practice)-313.9(guidelines.)-317.6(All)-305.6(10)-308.8(elected)-315.8(to)-306.7(proceed)-316.7(with)-312.5(treatment)]TJ
0 -1.2266 TD
[(using)-248(IMRT)-248.4(and)-246.2(concurrent)-251.5(chemotherapy)-252.9(at)-246.6(Mayo)-245.8(Clinic)-247.4(\(9\))]TJ
0 -1.2203 TD
[(or)-357.6(at)-360.4(another)-357.9(institution)-365.7(under)-356.1(the)-357.8(direction)-358(of)-357.3(Mayo)-359.6(Clinic)]TJ
T*
[(physicians)-236(\(1\).)-237.3(All)-229.8(10)-233(patients)-231.2(had)-233.5(tissue)-235.5(conrmation)-231.4(of)-237.2(ATC)]TJ
0 -1.2266 TD
[(by)-293.4(expert)-301.7(thyroid)-296.5(pathologists)-296.7(at)-297.2(our)-289.4(institution.)-305.4(For)-292.4(8)-290.4(cases,)]TJ
0 -1.2203 TD
[(pathological)-643.7(material)-643.3(was)-634.7(available)-640.2(for)-642.6(conrmatory)-640.6(re-)]TJ
T*
[(review)-518.5(conducted)-518.3(by)-514.7(a)-511.7(single)-521.9(expert)-516.6(pathologist)-516.7(\(R.V.L.\).)]TJ
0 -1.2266 TD
[(None)-417(of)-407.9(the)-414.7(10)-403.7(patients)-414.6(had)-410.6(evidence)-414.3(of)-407.9(distant)-416.4(metastatic)]TJ
0 -1.2203 TD
[(disease)-394.2(\(stage)-391.8(IVC\))-384.9(based)-393.8(on)-385.5(physical)-389.4(examination,)-391.7(routine)]TJ
T*
[(labs,)-568.1(and)-562.3(imaging)-560.1(including)-562.9(computed)-568.4(tomography)-561.1(\(CT\))]TJ
0 -1.2266 TD
[(scans)-390.5(of)-388.9(the)-383.1(chest)-390(and)-385.3(abdomen,)-386.5(and)-385.3(positron)-389.4(emission)-386.4(to-)]TJ
0 -1.2203 TD
[(mography)-317.6(\(PET\)/CT.)-314.6(After)-312.8(treatment,)-315.1(patients)-319.8(were)-312(usually)]TJ
T*
[(seen)-333.3(for)-326.4(follow-up)-334(every)-328.1(3)-322(months)-331.4(for)-326.4(the)-326.2(rst)-334.3(2)-322(years,)-331.2(then)]TJ
T*
[(every)-321.8(6)-322(months)-318.7(for)-320.1(an)-325.4(additional)-319.4(3)-315.7(years.)-324.9(Median)-317.9(follow-up)]TJ
0 -1.2266 TD
[(was)-280.7(36)-283.6(months.)]TJ
1.1128 -1.2203 TD
[(Ou)20.9(r)-285.2(i)0(n)18.4(t)0(e)18.6(n)0(t)15.1(i)15.4(on)-278(wa)17.8(s)-279.5(t)0(o)-275.1(u)0(t)17.1(i)0(l)18.2(i)0(z)22.2(e)-284.4(ra)18.8(di)18.8(os)21.2(e)12.8(n)0(s)14.3(i)0(t)21.3(i)0(z)15.9(i)15.4(ng)-279.7(c)13.4(h)0(e)15.7(m)15.1(ot)15.7(he)15.7(ra)25.1(py)]TJ
-1.1128 -1.2203 TD
[(as)-386.5(we)23.8(ll)-380.1(as)-380.2(se)17.8(ve)18.3(ra)18.8(l)-389.2(a)0(d)16.5(d)0(i)18.8(t)12.2(io)19(na)22.4(l)-395.6(c)13.4(yc)15.3(l)15.4(e)0(s)-386.9(o)0(f)-376.3(p)0(o)14.8(s)0(t)17.2(r)0(a)25.1(d)0(i)18.8(a)0(t)19(i)0(o)19(n)-389.1(th)15.1(er)18.4(a)13.1(p)0(y)]TJ
0 -1.2266 TD
[(an)16.1(d/)19.3(or)-313.3(pr)23.2(er)18.4(ad)16.5(i)15.4(a)0(t)19(i)0(o)19(n)-325.9(c)13.4(h)0(e)15.7(m)0(o)18.6(t)12.2(he)15.7(ra)18.8(py)19.5(,)-319.1(t)12.2(o)-325.2(c)13.4(on)19.1(si)14.1(st)-311.6(of)-306.7(do)19.5(xo)14(ru)23.2(bi)17.3(c)13.4(i)0(n)]TJ
0 -1.2203 TD
[(co)16.9(mb)17(in)18.4(e)12.7(d)-515.2(wi)20.1(t)12.2(h)-515.5(do)19.5(c)13.4(e)0(t)18.6(a)0(x)17.3(e)12.7(l)-515.7(\()12.2(da)16.5(y)-510.3(1)13.1(:)-515.1(d)0(o)19.5(c)13.4(et)12.3(a)13.1(x)0(e)16.9(l)-509.4(60)-144.4(mg)17(/m)]TJ
6.7246 0 0 5.9768 529.3983 302.3432 Tm
(2)Tj
8.9663 0 0 8.9663 537.3353 298.3748 Tm
-.0131 Tc
[(an)-13.1(d)]TJ
-25.0134 -1.2203 TD
0 Tc
[(do)13.2(xo)20.4(ru)23.2(bi)17.3(ci)22.5(n)-578.8(6)13.1(0)-157.6(m)0(g)23.3(/)0(m)]TJ
6.7246 0 0 5.9768 400.8188 291.4015 Tm
(2)Tj
8.9663 0 0 8.9663 409.3227 287.433 Tm
[(ad)22.8(mi)17.9(ni)18.4(st)17.2(e)12.8(r)0(e)18.4(d)-572.1(in)18.4(tr)17.8(av)18.7(e)12.7(n)0(o)12.8(u)0(s)22.6(l)0(y)17.3(;)-572(da)22.8(y)-573.5(2)13.1(:)]TJ
-10.7363 -1.2266 TD
[(pe)17.7(gy)16.5(la)22.3(te)18.6(d)-319.1(F)0(i)17.3(l)0(g)23.7(r)0(a)18.8(s)0(t)17.2(i)0(m)17.9(,)-312.7(6)-157.6(m)0(g)-311.8(s)0(u)22.6(b)0(c)21.6(u)0(t)17.1(a)0(n)16.1(e)12.7(ou)14.8(sl)20.4(y)-314.2(a)0(d)16.5(m)0(i)17.9(n)0(i)24.7(s)0(t)17.2(e)0(r)18.4(e)0(d)]TJ
/F5 1 Tf
24.9123 0 TD
(>)Tj
/F4 1 Tf
.7651 0 TD
(24)Tj
-25.6773 -1.2203 TD
[(ho)12.8(ur)23.2(s)-336.4(a)13.1(f)12.2(t)0(e)12.3(r)-329.5(c)13.4(o)0(m)18.6(p)0(l)14.1(e)12.8(ti)21.3(on)-322.3(of)-325.7(ch)16.3(e)12.7(m)0(o)18.6(t)0(h)15.1(e)12.8(ra)18.8(py)19.5(,)-331.7(a)13.1(ll)-323.2(ad)16.5(m)15.1(i)0(n)18.4(i)0(s)20.4(t)0(e)18.6(r)0(e)18.4(d)-331.8(on)]TJ
T*
[(an)-300.1(ou)21.2(tp)17.1(a)13.1(t)0(i)15(e)12.8(nt)-294.7(ba)15(si)20.4(s\))-292.6(\(1)19(8\))19(.)-306.4(I)0(n)19.8(d)0(i)18.8(v)0(i)21(d)0(u)20.9(a)0(l)15.9(i)0(z)22.2(a)0(t)19(i)0(o)19(n)-306.9(of)-294.1(th)15.1(is)-295.7(c)13.4(h)0(e)15.7(m)15.1(ot)15.7(he)15.7(r-)]TJ
T*
[(ap)18.1(y)-206.8(r)0(e)18.4(g)0(i)17.3(m)0(e)21.5(n)-212(g)14.5(u)0(i)14.1(d)0(e)22.4(l)0(i)18.2(n)0(e)15.7(,)-205.3(ho)19.1(we)17.4(ve)18.3(r,)-193.3(wa)17.8(s)-210(a)13.1(ll)18.2(ow)20.9(ed)-198.9(at)-202.3(t)12.2(h)0(e)-199.3(d)0(i)18.8(s)0(c)18.4(r)0(e)18.4(t)12.2(io)19(n)]TJ
ET
q
398.337 0 0 143.49 108.057 74.041 cm
/Im1 Do
Q
BT
/F7 1 Tf
8.9663 0 0 8.9663 167.9243 57.2598 Tm
[(SCHEME)-333.3(1.)]TJ
/F4 1 Tf
6.4367 0 TD
[(Distribution)-336.7(of)-338.4(ATC)-333.4(Patients)-338.7(seen)-333.3(during)-338.9(study)-333(period.)]TJ
/F6 1 Tf
-18.2479 77.2217 TD
(26)Tj
47.6495 0 TD
[(FOOTE)-331.4(ET)-338.7(AL.)]TJ
ET
endstream
endobj
37 0 obj
<>stream
Adobe d C
+>
s !1AQa"q2B#R3b$r%C4Scs5D'6Tdt&
EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz ? Aj9|95Nj9sW5NjS5sTj\9sTa\S/:;kQiw{vIZʱܰ"sɾ?? ?Y Y? ?Y Y?p, , Vo\ p?7G? . E՛# S E՛# "j ˀg 5f g ? 3Y Y? p, VoOVoOVoOVo\ p?7G? . E՛# S E՛# "j ˀg 5f g g 5f g g 5f g? 3 ? 3 Y Y? p, , , VoOVoOVow\ p?7G? p?7G? p?7G? . E՛# S E՛# S E՛# "j ˀg 5f g g 5f g ? 3 ? 3 ? 3 Y Y? ?Y Y? ?Y Y? p, VoOVo\ p?\yDM[C\-/tk-Z78h&9뚧5NjSsW5NjT\9sT\+/6lٷ͛6Vny͕+6je|mh/u
Vo7M7͉ORY+ED&io?0<{moEui.. kkhԐ"
ӭsy~h)y,νmu A&WJ`̿;jYm Xׯ4f)$Vs$hFO<=+[๊gnpeYbBG>Z|yz[[hn#@+mrHinW^ FF.;":,uy4-3\}BRVr3H}W旐|[VK~/#"1_M_J`/&_haUhd[^_XI-+ќBq+Pݫ;;qx<%Ͱ5LD97(OL cZfm&tUA_s/l__bvگQLE:Ҿ0&siy$E,jid婶
Gyۊ*=eo1zt{
#QK q3s,L:]eo2j[IEխ`xzК3R0mW7&'1P !<*?yq/hr+o?-kdK[I^Jgmk,@W'm%e_5WW$sd*-
A?K~pڲ]]۩y-]%_L>2T)$Am~~\$M^>\ڜYдͱ+-ۋ['$GB=?M*zZ5jz0IԬ.iEeV&50 O}7~aԣk,>QwEh61e_cgwm{:LH~#]5zJq r]&G~:Z~KfGĞur8/ c,|kug{mXETt
F|3Kյ
^LZН.^EYc6SAKFۥXy -"3p
ч!ɿ>J_.jKy-C*hʨ5)fN!rtrEgF
ӓ
a?6?/<ŮK7ZEGuTW
~u~Xh:h7r%8Xѣl)+̞pl2~Zh+gsMBg'xJt4=eڗ]7XkjZɘi*;JTG
J|נSg1BdM !rfHPY bz 2w~Wj>`Aעi=v (Rh#ਅܞ_|_Ϳ,vp-+pXG*+ji$2y=⺬syr6T{E+"Ch?_Z&p\YRVoLU V9c[ȒyZ=HMb+ŖUJyBq?l5ڸ?o <M~f_GL苎>q\_ :;MU[{THG-2H8VFT0 5 Eֳn
>z\LƠ$J~#~jBj5b2&:-р?/~nW`:R"IBr!JF]Č_͟?Rbӵb;[ s4hoI_C~`WK]sTաM M)e=;/o:|nYbG?$fEjj|ijg?.f8oeqJ%ʎEe?,Yyf͛+6lٳe͛+/6c6lٲf͛/+/6W|ٲf͗6a